Ontario HIV Treatment Network
15
1
1
11
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 50/100
13.3%
2 terminated/withdrawn out of 15 trials
84.6%
-1.9% vs industry average
27%
4 trials in Phase 3/4
9%
1 of 11 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
The T Cell Activator of Cell Killing ("TACK") IT ON" STUDY
Role: collaborator
Tele-Coaching Community-Based Exercise (CBE) Study
Role: collaborator
The HPV-SAVE Study Team: HPV Screening and Vaccine Evaluation in Men Who Have Sex With Men
Role: collaborator
Combination Vaccination Before HIV Treatment Interruption
Role: collaborator
The Effects of Statin Therapy on Coronary Flow Reserve and Inflammatory Markers in HIV-Positive Patients
Role: collaborator
Evaluation of Enhanced Syphilis Screening Among HIV-positive Men
Role: collaborator
Micronutrients and Antioxidants in HIV Infection
Role: collaborator
Trial of Citalopram for the Prevention of Depression
Role: collaborator
Influenza Vaccine in HIV
Role: collaborator
Screening for HIV-Associated Anal Cancer
Role: collaborator
Lactate Metabolism Study in HIV Infected Persons
Role: collaborator
Non-alcoholic Fatty Liver Disease (NAFLD) in HIV: The Role of Nutritional Interventions
Role: collaborator
Effects of an Evidence Service on Community-based AIDS Service Organizations' Use of Research Evidence
Role: lead
Supportive Therapy for Adherence to ART(STAART)
Role: collaborator
Multicenter Trial of Immunologic Markers to Predict Long Term Virologic Outcomes
Role: collaborator
All 15 trials loaded